bad reaction to semaglutide Dermal Hypersensitivity Semaglutide: Two Case Reports Semaglutide, also known as Ozempic,

Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4

They were developed using structural modifications such as acylation with a fatty acid chain to facilitate albumin binding increasing its half-life to 13h after a single injection with Liraglutide, and then further refined to an increased human plasma half-life of 160h for Semaglutide which is also protected from dipeptidyl peptidase-4 cleavage

Zhou W, Li H, Huang T, et al

Approval is not guaranteed

If a dose of a once-weekly GLP-1 medication is missed, patients should follow product-specific guidance